NICOTINE & METABOLITES; SERUM

The NICOTINE & METABOLITES; SERUM test quantifies nicotine and its metabolic products in blood serum—commonly cotinine and trans-3'-hydroxycotinine—using sensitive laboratory methods to detect recent tobacco or nicotine product exposure. By measuring these biomarkers, the test provides an objective assessment of the intensity and timing of nicotine intake, which is more reliable than self-reporting. This information is important for clinicians to monitor smoking status, guide cessation strategies, assess secondhand exposure, and inform perioperative or occupational health decisions.

The test is suitable for patients enrolled in smoking-cessation programmes, individuals requiring confirmation of abstinence, people undergoing pre-surgical evaluation, and clinicians who need to distinguish between tobacco use and nicotine-replacement therapies. Collection is performed via a single venous blood draw and can be arranged at your Dubai home through Touch Connect’s lab-at-home service, with results provided to you and your healthcare provider to support clinical management and counselling.

• Nicotine (Serum)
• Cotinine (Serum)
• Trans-3'-Hydroxycotinine
• Anabasine
• Anatabine

• To confirm recent smoking or nicotine product use
• During follow-up of smoking‑cessation programmes to verify abstinence
• Pre-operative assessment to evaluate perioperative risk from tobacco exposure
• Occupational, insurance, or medico-legal screening when exposure must be documented
• Assessing maternal tobacco exposure during prenatal care when clinically indicated

• Objective, lab‑grade measurement of nicotine exposure
• Supports personalised smoking‑cessation and clinical decision-making
• Ability to differentiate tobacco use from nicotine-replacement products via minor alkaloids
• Convenient at‑home blood collection across Dubai with secure reporting
• Timely results to integrate with medical care and counselling

• At‑home venous blood draw (serum) performed by a certified phlebotomist
• No fasting required prior to sample collection
• Inform the collector about nicotine replacement therapy, e‑cigarette use, medications, or pregnancy
• Results typically available within 48–72 hours and delivered securely to you and your clinician